Oncology News

Patients with hepatocellular carcinoma and severely deficient serum 25-hydroxyvitamin D3 levels were more likely to face mortality, compared with those with higher levels, according to data.

Patients with cirrhosis who underwent surveillance for hepatocellular carcinoma had earlier tumor detection rates, a longer rate of survival and were more likely to receive curative vs. palliative treatment, according to results from a meta-analysis.

Individual genetic models produced 101 antimetabolites that may be effective in inhibiting tumor growth in hepatocellular cancer patients, according to new data.

Consuming black or green tea daily did not reduce the risk for developing liver or other major cancers, according to recent study data.

Three-dimensional MRI scans differentiated live and dead tumor tissue, providing more accuracy than 2-D images of how successful chemotherapy is for patients with liver cancer, according to a press release.

Members of the All-Party Parliamentary Hepatology Group have asked the National Health Service in the United Kingdom to show more concern about the rise of liver disease.

Researchers used Cox proportional hazard analysis of 256 HIV-infected patients with hepatocellular carcinoma (HCC) to develop the SHILCA score, which considered multiple baseline variables that each independently predicted survival.

Hepatocellular carcinoma patients without detectable disease after resection or ablation experienced no improvement in recurrence-free survival after being assigned sorafenib tablets in an investigational trial, according to a press release.

In a retrospective cohort study, researchers at Seoul National University Hospital in South Korea analyzed data from 329 patients with early-stage hepatocellular carcinoma (eHCC). Single tumors were defined as being less than 3 cm. Patients underwent either surgical resection (SR; n=128) between January 2006 and December 2011 or radiofrequency ablation (RFA; n=201) between July 2007 and December 2011. SR patients were primarily men (73.4%; mean age, 55.6 years), and the RFA group was 70.1% male (mean age, 60.8 years).

The hepatitis C virus has a profound negative impact on patients’ quality of life, both in its clinical manifestations and its overall economic burden, according to recent study data.